New drug E7386 tested in patients with advanced cancer
NCT ID NCT03833700
First seen Feb 28, 2026 · Last updated May 18, 2026 · Updated 8 times
Summary
This early-phase study tests the safety and tolerability of a new drug called E7386 in 70 people with advanced solid tumors, including colorectal cancer. Participants have tumors that cannot be removed by surgery or have come back, and no standard treatments are available. The main goal is to find safe doses and understand side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai Trial Site #1
Chuo Ku, Tokyo, Japan
-
Eisai Trial Site #2
Kashiwa, Chiba, Japan
-
Eisai Trial Site #3
Nagaizumi-cho, Shizuoka, Japan
-
Eisai Trial Site #4
Fukuoka, Japan
-
Eisai Trial Site #5
Sapporo, Hokkaido, Japan
-
Eisai Trial Site#6
Osaka, Japan
-
Eisai Trial Site#7
Nagoya, Aichi-ken, Japan
-
Eisai Trial Site#8
Sendai, Miyagi, Japan
Conditions
Explore the condition pages connected to this study.